CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and ...

Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd.

Extracellular vesicles (EVs) loaded with customizable anti-cancer antisense oligonucleotides suppressed cancer growth.

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.